- ISIN
- IL0011794802
- CUSIP
- 90117G105
- Sector
- Technology
- Industry
- Software - Infrastructure
- IPO Date
- Aug 31, 2021
Highlights
- Market Cap
- $4.02B
- Enterprise Value
- $3.92B
- EPS (TTM)
- $0.29
- PE Ratio
- 56.36
- PEG Ratio
- 0.11
- Total Revenue (TTM)
- $496.43M
- Gross Profit (TTM)
- $416.33M
- EBITDA (TTM)
- $84.98M
- Year Range
- $11.02 - $19.98
- Target Price
- $19.67
- ROA (TTM)
- 7.55%
- ROE (TTM)
- 14.08%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CLBT Performance Chart
Cellebrite DI Ltd. (CLBT) is down 10.5% since the beginning of the year. At $16 per share, CLBT is trading 19.3% below its 52-week high of $20.
Loading charts...
Returns By Period
Cellebrite DI Ltd. (CLBT) has returned -10.54% so far this year and 10.56% over the past 12 months.
Cellebrite DI Ltd.
- 1D
- 1.19%
- 1M
- 25.62%
- 6M
- -10.64%
- YTD
- -10.54%
- 1Y
- 10.56%
- 3Y*
- 32.21%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.79%
- 1M
- 1.13%
- 6M
- 7.71%
- YTD
- 9.79%
- 1Y
- 20.06%
- 3Y*
- 18.60%
- 5Y*
- 11.43%
- 10Y*
- 13.27%
CLBT Monthly Returns History
Based on dividend-adjusted daily data since Aug 31, 2021, CLBT's average daily return is +0.09%, while the average monthly return is +1.64%. At this rate, an investment would double in approximately 3.6 years.
Historically, 50% of months were positive and 50% were negative. The best month was Feb 2024 with a return of +32.4%, while the worst month was Nov 2021 at -30.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.
On a daily basis, CLBT closed higher 49% of trading days. The best single day was Nov 13, 2025 with a return of +20.7%, while the worst single day was Apr 6, 2022 at -13.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -18.41% | -9.31% | 3.30% | -5.66% | 13.31% | -0.88% | 10.48% | -10.54% | |||||
| 2025 | 9.12% | -22.80% | 4.69% | 1.85% | -15.72% | -4.08% | -12.62% | 17.31% | 12.99% | -7.93% | -1.17% | 6.94% | -18.16% |
| 2024 | 4.39% | 32.41% | -7.44% | -2.44% | -1.48% | 12.21% | 14.64% | 24.53% | -1.29% | 7.78% | 11.18% | 9.17% | 154.39% |
| 2023 | 25.92% | 12.02% | -0.98% | -11.17% | 6.65% | 24.78% | 8.47% | 3.07% | -4.97% | -12.68% | 26.50% | 2.49% | 98.62% |
| 2022 | -25.19% | 18.33% | -9.86% | -16.41% | -9.91% | 5.81% | -0.98% | -3.96% | -19.18% | 23.21% | -6.42% | -3.54% | -45.64% |
| 2021 | -2.10% | -9.66% | 20.63% | -30.17% | 2.82% | -23.40% |
Benchmark Metrics
Cellebrite DI Ltd. has an annualized alpha of 10.83%, beta of 0.94, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since August 31, 2021.
- This stock participated in 121.30% of S&P 500 Index downside but only 116.19% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10.83%
- Beta
- 0.94
- R²
- 0.10
- Upside Capture
- 116.19%
- Downside Capture
- 121.30%
Return for Risk
Risk / Return Rank
CLBT ranks 52 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cellebrite DI Ltd. (CLBT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLBT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.41 | ||
| Sortino ratioReturn per unit of downside risk | -1.50 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.29 | -0.21 |
| Calmar ratioReturn relative to maximum drawdown | 0.24 | 2.21 | -1.97 |
| Martin ratioReturn relative to average drawdown | 0.50 | 9.61 | -9.11 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cellebrite DI Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cellebrite DI Ltd. was 67.74%, occurring on Sep 30, 2022. Recovery took 355 trading sessions.
The current Cellebrite DI Ltd. drawdown is 37.96%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -67.74%Sep 2022 | 1y 13d | 1y 5mo | 2y 5moSep 2021 - Mar 2024 |
2026 bear market2026 | -57.58%Apr 2026 | 1y 2mo | — | 1y 5moFeb 2025 - now |
2024 correction2024 | -15.54%Apr 2024 | 1mo 12d | 1mo 28d | 3mo 10dMar 2024 - Jun 2024 |
2021 correction2021 | -13.52%Sep 2021 | 6d | 7d | 13dSep 2021 - Sep 2021 |
2024 correction2024 | -11.27%Aug 2024 | 7d | 10d | 17dJul 2024 - Aug 2024 |
Drawdown Indicators
| CLBT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.74% | -56.78% | -10.96% |
Max Drawdown (1Y)Largest decline over 1 year | -43.61% | -9.10% | -34.51% |
Max Drawdown (3Y)Largest decline over 3 years | -57.58% | -18.90% | -38.68% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -37.96% | -1.24% | -36.72% |
Average DrawdownAverage peak-to-trough decline | -34.69% | -10.71% | -23.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.06% | 2.09% | +18.97% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cellebrite DI Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cellebrite DI Ltd. is priced in the market compared to other companies in the Software - Infrastructure industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CLBT, comparing it with other companies in the Software - Infrastructure industry. Currently, CLBT has a P/E ratio of 56.4. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CLBT compared to other companies in the Software - Infrastructure industry. CLBT currently has a PEG ratio of 0.1. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CLBT relative to other companies in the Software - Infrastructure industry. Currently, CLBT has a P/S ratio of 8.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CLBT in comparison with other companies in the Software - Infrastructure industry. Currently, CLBT has a P/B value of 8.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CLBT
Add Cellebrite DI Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CLBT